Nabriva Therapeutics, a biopharmaceutical company developing antibiotics to treat serious infections, with a focus on the pleuromutilin class of antibiotics, says Will Sargent has joined the company as Vice President, Commercial Strategy and Investor Relations, a newly created position. Sargent will be based at the company’s US headquarters in King of Prussia, PA, US.
Sargent will lead the development of a commercial strategy for the launch of lefamulin for the treatment of community-acquired bacterial pneumonia (CABP) and corporate communications/investor relations; he will also support the lefamulin development programme for additional indications.
Sargent joins Nabriva with two decades of experience in the biopharmaceutical industry. Most recently, he was Vice President of the Orthopaedic Business Unit at Auxilium Pharmaceuticals.
Before Auxilium he was a biotechnology equities analyst at Bank of America and held multiple commercial roles at Amgen and Immunex.
